Abstracts tagged "Cardiovascular disease"

Abstract Number: 1488 • 2016 ACR/ARHP Annual Meeting
Comparison Between Carotid Ultrasonography and Coronary Artery Calcification Score to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis
Lucia Cristina Domínguez-Casas¹, Leyre Riancho-Zarrabeitia¹, Carlos Fernández-Díaz¹, Nuria Vegas-Revenga², Alfonso Corrales¹, José Antonio Parra³, Montserrat Santos-Gómez⁴, Virginia Portilla², Patrick H Dessein⁵, Ricardo Blanco¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Radiology Division, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Carotid ultrasonography (CU) and coronary artery calcification score (CAC) evaluated by multidetector computed tomography (MDCT) scanner are useful in detecting subclinical atherosclerosis in…
Abstract Number: 2169 • 2016 ACR/ARHP Annual Meeting
Presence of Cardiovascular Risk Factors Across Different Inflammatory Joint Disease Entities: Results from a Norwegian, Multi-Centre Project
Grunde Wibetoe¹, Eirik Ikdahl², Silvia Rollefstad², Anne Salberg³, Dag Magnar Soldal⁴, Tore K Kvien⁵, Glenn Haugeberg⁶ and Anne Grete Semb⁷, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Martina Hansens Hospital, Bærum, Norway, ⁷Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: EULAR recommendations for cardiovascular disease (CVD) risk management in inflammatory joint diseases (IJD) advocates annual CVD risk assessments to reduce the increased CVD risk.…
Abstract Number: 3101 • 2016 ACR/ARHP Annual Meeting
Lipoprotein Profile and Serum Glycoprotein Acetylation As Markers of Cardiovascular Risk in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Yenealem Temesgen-Oyelakin², Maureen Sampson³, Aditya Joshi⁴, Alice Fike⁵, Michael Davis⁶, Taufiq Salahuddin⁷, Balaji Natarajan⁷, Joseph Lerman⁷, Zerai G. Manna⁸, Amit Dey⁹, Marcus Chen⁷, Sarfaraz Hasni⁸, Nehal N. Mehta⁷, Alan Remaley⁷ and Mariana Kaplan¹⁰, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases,, National Institutes of Health, Bethesda, MD, ³Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷NHLBI, National Institutes of Health, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹National Institutes of Health, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD
Background/Purpose: The risk of atherosclerotic cardiovascular disease (CVD) is significantly increased in systemic SLE compared to age and gender matched controls. The implementation of nuclear…
Abstract Number: 524 • 2016 ACR/ARHP Annual Meeting
A Self-Determination Theory Based Intervention to Increase Levels of Cardiorespiratory Fitness, Self-Determined Motivation, Physical Activity and Improve Health Outcomes Among Patients Living with Rheumatoid Arthritis
Joan Duda¹, Sally Fenton^1,2, Jet Veldhuijzen van Zanten^2,3, George Metsios^2,4, Peter Rouse⁵, Nikos Ntoumanis⁶, Chen-an Yu⁷, Yiannis Koutedakis⁸ and George D. Kitas^1,2, ¹School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Department of Physical Activity Exercise and Health, University of Wolverhampton, Walsall, United Kingdom, ⁵Department for Health, University of Bath, Bath, United Kingdom, ⁶School of Psychology & Speech Pathology, Curtin University, Perth, Australia, ⁷School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom, ⁸University of Wolverhampton, Wolverhampton, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) may cause joint damage leading to physical dysfunction and associates with increased cardiovascular (CV) risk. Regular physical activity (PA) can attenuate…
Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting
Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Claire Rempenault¹, Thomas Barnetche², Jacques Morel³, Cédric Lukas⁴, Cécile Gaujoux-Viala⁵, Bernard Combe⁶ and Charlotte Hua⁷, ¹Rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
Abstract Number: 2170 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom
Ernest H. Choy¹, Roxanne Cooksey², Sinead Brophy², Jonathan Kennedy², Fabiola Fernandez-Gutierrez³, Ruth Davies⁴, Timothy Pickles⁵ and Vincent Piguet⁶, ¹CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ²College of Medicine, Swansea University, Swansea, United Kingdom, ³Cancer Research UK Manchester Institute, Manchester, United Kingdom, ⁴CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁶Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Compared with cardiovascular (CV) risk in rheumatoid arthritis (RA), precise CV risk in psoriatic arthritis (PsA) and psoriasis is less established, particularly the relative…
Abstract Number: 3103 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Prevalent Cardiovascular Disease in African American Systemic Lupus Erythematous Patients
Ashira Blazer¹, Robert M Clancy², H. Michael Belmont³, Peter M. Izmirly³, Androo Markham⁴ and Jill P. Buyon⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, located on chromosome 22q12.3, have been associated with excess renal risk in African Americans…
Abstract Number: 35 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study
Mette Holland-Fischer¹, Ulrik Tarp², Reimar W. Thomsen³ and Mette Nørgaard³, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, AArhus, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with Rheumatoid Arthritis (RA). Patients with RA do also have an increased…
Abstract Number: 808 • 2015 ACR/ARHP Annual Meeting
Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE
Ashira Blazer¹, Andrew Markham², Sara Rasmussen³, Jill P. Buyon⁴, H. Michael Belmont⁵, Shilpi Mehta-Lee⁶, Janet Nwaukoni⁴, Peter M. Izmirly⁷ and Robert Clancy⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Hosp for Joint Disease, New York, NY, ⁶Obstetrics and Gynecology, New York University School of Medicine, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: With higher prevalence of renal and cardiovascular diseases (CVD), as well as HTN, African American (AA) SLE patients experience accelerated damage accrual and excess…
Abstract Number: 1523 • 2015 ACR/ARHP Annual Meeting
Ischemia Modified Albumin Levels in Rheumatoid Arthritis
Ali Ugur Uslu¹, Adem Kucuk², Sevket Balta³, Sevket Arslan⁴, Levent Tekin⁵, Sami Kucuksen⁶, Aysun Toker⁷ and Mehmet Kayrak⁸, ¹Internal Medicine, Eskisehir Military Hospital, Eskisehir, Turkey, ²Necmettin Erbakan U Meram T F, Necmettin Erbakan U Meram T F, Konya, Turkey, ³Cardiology, Eskisehir Military Hospital, Eskisehir, Turkey, ⁴Allergy and Clinical Immunology, Necmettin Erbakan University, Konya, Turkey, ⁵Physical Medicine and Rehabilitation, Beyhekim State Hospital, Konya, Turkey, ⁶MD, kONYA, Turkey, ⁷Biochemistry, Necmettin Erbakan University, Konya, Turkey, ⁸Necmettin Erbakan University, Division of Cardiology, Konya, Turkey
Background/Purpose: Cardiovascular diseases, among which atherosclerotic heart disease, are known to be one of the most important mortality and morbidity causes in patients with Rheumatoid…
Abstract Number: 1624 • 2015 ACR/ARHP Annual Meeting
Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis. Alterations Related to Cardiovascular Disease and Endothelial Dysfunction
Nuria Barbarroja^1,2, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Yolanda Jiménez Gómez¹, MariCarmen Abalos-Aguilera¹, Pedro Segui³, Pilar Font¹, Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega¹, M. Carmen Castro Villegas¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera¹, ¹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ³IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain
Background/Purpose: Monocytes play a key role in the pathogenesis of the cardiovascular disease (CVD). Three monocyte subsets have been described based on their CD14 and…
Abstract Number: 2270 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis
Karen Soikkeli¹ and Glenn Ehresmann², ¹Graduate Nursing (Family Nurse Practitioner Program), Azusa Pacific University, Diamond Bar, CA, ²Rheumatology, Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, Los Angeles, CA
Background/Purpose: Despite the fact that patients with rheumatoid arthritis (RA) experience a 50-60% increased risk of developing cardiovascular disease (CVD), substantial gaps remain in the…
Abstract Number: 3168 • 2015 ACR/ARHP Annual Meeting
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov⁴, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria, ⁴Clinic of Rheumatology, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria
Background/Purpose: We have not found a study determining cardiovascular (CV) risk in the different stages of gout. This led us to use a complex multimodal…
Abstract Number: 36 • 2015 ACR/ARHP Annual Meeting
The Incidence of Cardiovascular Events in Patients with Rheumatoid Arthritis: a 15 Years Observational Cohort Study
Koen Laan¹, Rabia Agca^1,2, Alexandre E. Voskuyl³, Maarten Boers², Willem Lems² and Mike T. Nurmohamed^1,2, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands
Background/Purpose: The increased risk for cardiovascular (CV) disease in rheumatoid arthritis (RA) is well established. However, there are relatively few contemporary cohort studies with long…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].